TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07633873: An Open-label, Multicenter Randomized Phase III Study of SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy as First-Line Treatment for Patients With PD-L1-Positive Locally Advanced or M

Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 500 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$20,993,280

Rescue Site Savings

+$13,842,444

Unlock Full NCT07633873 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07633873 Rescue Dossier →